Present and Future Experiments in Non-equilibrium Reactor Antineutrino Energy Spectrum

Considerable efforts that have been undertaken in the recent years in low energy antineutrino experiments require further systematic investigations in line of reactor antineutrino spectroscopy as a metrological basis of these experiments. We consider some effects associated with the non-equilibrium of reactor antineutrino radiation and residual antineutrino emission from spent reactor fuel in contemporary antineutrino experiments.Comment: 7 pages, 5 figures; Talk presented at International Conference NANP-2005, Dubna, Russia, Jun.-2005; Submitted to Phys. Atom. Nuc

ТЕКТОНИКА И ЭВОЛЮЦИЯ ЛИТОСФЕРЫ ВОСТОЧНОЙ ЧАСТИ МОНГОЛО-ОХОТСКОГО ОРОГЕННОГО ПОЯСА

oai:oai.gtcrust.elpub.ru:article/7The article describes tectonics and the deep structure of the lithosphere in the eastern fragment of the Mongol-Okhotsk orogenic belt according to results of analysis of the geological and geophysical database. With account of palinspastic reconstructions, the model is developed to show the most probable paleogeodynamics of the lithosphere in the Mongol-Okhotsk orogenic belt and its heterochronous terrains.На основе анализа комплекса геолого-геофизических данных проведено описание тектонического и глубинного строения литосферы восточной части Монголо-Охотского орогенного пояса. С учетом глобальных палинспастических реконструкций составлена наиболее вероятная палеогеодинамическая модель формирования литосферы Монголо-Охотского орогена и слагающих его разновозрастных террейнов.

GABRIELA : a new detector array for gamma-ray and conversion electron spectroscopy of transfermium elements

With the aid of the Geant4 Monte Carlo simulation package a new detection system has been designed for the focal plane of the recoil separator VASSILISSA situated at the Flerov Laboratory of Nuclear Reactions, JINR, Dubna. GABRIELA (Gamma Alpha Beta Recoil Investigations with the Electromagnetic Analyser VASSILISSA) has been optimised to detect the arrival of reaction products and their subsequent radioactive decays involving the emission of alpha- and beta-particles, fission fragments, gamma- and X-rays, and conversion electrons. The new detector system is described and the results of the first commissioning experiments are presented.Comment: 24 pages, Submitted to NIM

Study of 124^{124}Sn+136^{136}Xe fusion-evaporation: analysis of a rare-event experiment

7 pages, 4 figuresFusion-evaporation in the $^{124}$Sn+$^{136}$Xe system is studied using a high intensity xenon beam provided by the Ganil accelerator and the LISE3 wien filter for the selection of the products. Due to the mass symmetry of the entrance system, the rejection of the beam by the spectrometer was of the order of $5times10^8$. We have thus performed a detailed statistical analysis to estimate random events and to infer the fusion-evaporation cross sections. No signicant decay events were detected and upper limit cross sections of 172~pb, 87~pb and 235~pb were deduced for the synthesis of $^{257}$Rf, $^{258}$Rf and $^{259}$Rf, respectively

Клиническое исследование эффективности и безопасности препарата Визомитин®, глазные капли, у пациентов с возрастной катарактой

PURPOSE: The assessment of possibility to add a new indication for the registered pharmaceutical. Evaluation of safety and efficacy of Visomitin® compared to placebo in patients with age-related cataracts. METHODS: A randomized, double-blind, placebo-controlled clinical study of Visomitin® eye drops in patients with age-related cataracts was conducted in accordance with Good Clinical Practice guidance, the Declaration of Helsinki and the Russian regulatory requirements. The study included 80 patients (23 men and 57 women) aged 45 to 75 years with diagnosed age-related cataract. All subjects were randomized into two groups of 40 patients each. In the treatment group patients received Visomitin® eye drops and in the control group, patients were given placebo (vehicle, i.e. eye drops with the same composition as Visomitin® except for the active substance SkQ1) in the form of instillations of one drop per each eye three times daily for six months. The study comprised 7 monthly visits. The following standard ophthalmological examinations were used to evaluate the effectiveness of the therapy: visual acuity measurement, refractometry, biomicroscopy of the eye, ophthalmoscopy, tonometry, computer perimetry, densitometry. At certain visits lacrimal fluid was taken for evaluation of its antioxidant activity. Blood pressure and heart rate were measured as a part of safety evaluation which also included documentation of complaints and adverse events. Concomitant therapies were also documented. RESULTS: Analysis of safety parameters showed Visomitin® to be safe and well tolerated for patients with age-related cataract. Practically no adverse effects were documented during the study. In both groups a decrease of the number of patients with subjective complaints was observed. These complaints included: visual deterioration, dryness, grittiness, burning eyes, eye fatigue. The decrease of the number of complaints in the Visomitin® group was more pronounced than in the placebo group. During the first months of treatment an improvement of visual acuity was observed in both groups. This result can be explained by a protective effect of hypromellose contained in both Visomitin® and placebo. However, between the 4th and the 6th months, the improvement in visual acuity significantly slowed down in the placebo group, while positive dynamics remained the same in the Visomitin® group. At the end of the treatment visual acuity increased by more than 50% in Visomitin® group and remained at the level of 10-15% in the placebo group (statistically significant difference between placebo and Visomitin® groups,